Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 31 December 2024
- Conf. stmt due
- 11 March 2027
- Last conf. stmt
- 25 February 2026
Sage Therapeutics Limited
- Incorporated
- 1 March 2017 (9 years)
- Industry
- Manufacture of pharmaceutical preparations (21200) Wholesale of pharmaceutical goods (46460)
- Directors
- Brian Everett AckermanTimothy Carroll DecJack Antoine Khattar
- Owned by
- Supernus Pharmaceuticals, Inc.
- Accounts type
- Small
- Region
- Greater London
- Address
- C/o Company Secretarial Department280 BishopsgateLondonEC2M 4AG
Officers 5 active
Officer details are public data from the Companies House register.
Ackerman, Brian Everett
Director · Appointed 9 October 2025
American
Born April 1984 (42)
Dec, Timothy Carroll
Director · Appointed 9 October 2025
American
Born April 1958 (68)
Khattar, Jack Antoine
Director · Appointed 9 October 2025
American
Born July 1961 (65)
Roecklein, Bryan Alfred
Director · Appointed 9 October 2025
American
Born May 1959 (67)
Corporate Secretary · Appointed 1 March 2017
Officer history (5 former)
9 October 2025
Appointed Ackerman, Brian Everett as Director
9 October 2025
Appointed Dec, Timothy Carroll as Director
9 October 2025
Appointed Khattar, Jack Antoine as Director
9 October 2025
Appointed Roecklein, Bryan Alfred as Director
31 July 2025
Resigned Benecchi, Christopher as Director
31 July 2025
Resigned Marsh, Brandon George as Director
31 January 2025
Appointed Benecchi, Christopher as Director
21 January 2025
Resigned Flanagan, Michael Patrick as Director
29 October 2024
29 October 2024
Resigned Iguchi, Kimi Ellen as Director
25 October 2024
Appointed Flanagan, Michael Patrick as Director
25 October 2024
Appointed Marsh, Brandon George as Director
1 March 2017
1 March 2017
1 March 2017
Appointed Iguchi, Kimi Ellen as Director
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Supernus Pharmaceuticals, Inc.
Corporate entity · Notified 31 July 2025
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Corporation
Reg. no. Ein 20-2590184
Former controllers (1)
31 July 2025
Ceased Sage Therapeutics, Inc. — Owns 75–100% of shares
Financials
Balance sheet as at 31 December 2024 · small accounts
- Net Assets
- £2,094,431
- Cash
- £72,369
- Profit
- (£1,485)
- Employees
- 3
- Current Ratio
- 10.3x
- Return on Equity
- -0%
Trend
Net Assets
Balance sheet detail
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Current Assets | £2,275,136 | £1,995,956 | £1,593,091 |
| Cash | £72,369 | £65,603 | £6,675 |
| Creditors (< 1 year) | £220,301 | £269,802 | £146,859 |
| Net Current Assets | £2,054,835 | £1,726,154 | £1,446,232 |
| Net Assets | £2,094,431 | £1,765,750 | £1,485,828 |
| Shareholder Funds | £2,094,431 | £1,765,750 | £1,485,828 |
Filings
Filing history not loaded yet. See it on Companies House
Some other companies at this address
Other companies in this industry
Castleford
Runcorn
Northampton
Oxford
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →